simone biles glp-1 Black History of Health: Here's How Much Olympic Superstar

7,50,51 As researchers dive deeper into their multifaceted properties, these medications exhibit the potential to offer therapeutic benefits across a spectrum of diseases in human populations

These agents include thiazolidinediones (PPAR- agonists), dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, sodium-glucose co-transporter 2 (SGLT2) inhibitors, -glucosidase inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists

WL: Writing original draft, Writing review & editing

FDA Wegovy (semaglutide) Prescribing Information, NDA 215256, U.S

Originally developed for managing type 2 diabetes, these medications are now making headlines for their broader impact on weight, metabolic health and cardiovascular health